This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
Freelance translator and/or interpreter, Verified site user
Data security
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
Services
Translation
Expertise
Specializes in:
Patents
Materials (Plastics, Ceramics, etc.)
Engineering (general)
Mechanics / Mech Engineering
Medical: Pharmaceuticals
Science (general)
Manufacturing
Computers: Hardware
Also works in:
Mathematics & Statistics
Transport / Transportation / Shipping
Physics
Nuclear Eng/Sci
Law: Contract(s)
Metallurgy / Casting
Finance (general)
Engineering: Industrial
Economics
Computers: Software
Business/Commerce (general)
Biology (-tech,-chem,micro-)
Accounting
More
Less
Rates
All accepted currencies
U. S. dollars (usd)
Payment methods accepted
Check
Portfolio
Sample translations submitted: 2
Japanese to English: Chemical Patent General field: Law/Patents Detailed field: Chemistry; Chem Sci/Eng
Source text - Japanese http://v3.espacenet.com/publicationDetails/originalDocument?CC=JP&NR=2003327951A&KC=A&FT=D&date=20031119&DB=EPODOC&locale=en_EP
Translation - English DETAILED EXPLANATION OF THE INVENTION
[0001]
INDUSTRIAL FIELD OF APPLICATION
The present invention relates to a photocuring resin composition for sealing material and its applications, especially as a sealing material for a liquid crystal display and as a sealing material for an electroluminescent display. More particularly, the present invention relates to a photocuring resin composition for sealing material with excellent adhesive strength, moisture permeation resistance, and photocuring, and especially, excellent adhesive strength.
[0002]
PRIOR ART OF THE INVENTION
Panel displays using a variety of display elements have been developed and produced in the electronic and electrical fields in recent years. Many of these displays have display elements sealed in cells comprising a flat panel such as glass or plastic. Typical examples are a liquid crystal (LC) display and an electroluminescent (EL) display.
[0003]
A liquid crystal display usually has two glass substrates sealed around the edges by a sealing material and a liquid crystal sealed inside. Thermosetting epoxy resins have conventionally been used as sealing materials. Such thermosetting epoxy resins, however, must be heat-cured for about two hours at a high temperature of 150°C to 180°C, which poses a problem for raising productivity.
[0004]
An EL display is excellent on points such as high brightness, high efficiency, and high-speed response, and has attracted attention as a new generation of flat panel display. EL elements include inorganic EL elements and organic EL elements. Inorganic EL elements have been used, for example, in the backlights of timepieces. Organic EL elements are superior to inorganic EL elements on the points of high brightness, high efficiency, high-speed response, and multicolor display, but have low heat resistance, with a hot temperature resistance of usually about 80 to 100°C. This causes the problem that organic EL elements cannot be heated enough to cure, even using a thermosetting epoxy resin as a sealing material for sealing an organic EL display.
[0005]
Photocuring sealing materials capable of curing at a low temperature and speed have been developed in an attempt to solve these problems. These materials are photo-radical curing sealing materials and photocationic curing sealing materials.
[0006]
Photo-radical curing sealing materials mainly use acrylic resins and have the advantage of being able to use a variety of acrylate monomers and oligomers, but have the problems of insufficient moisture permeation resistance, reduced volumetric shrinkage, and poor adhesive power.
[0007]
Photocationic curing sealing materials mainly use epoxy resins and have relatively good adhesion, but have the problem that in recent years, applications of liquid crystal displays and EL displays have been used not just indoors, but under different environments outdoors, and when using the sealing materials conventionally used in liquid crystal displays, strong vibration or shock may damage airtightness inside cells in a liquid crystal display at times such as when using a cell telephone.
[0008]
Therefore, greater improvement in the adhesive strength of the sealing material for laminating substrates in a liquid crystal display or an EL display would be desirable.
[0009]
Therefore, the present inventors engaged in extensive research toward solving these problems, and discovered that using a photocuring resin composition comprising a compound having an oxetane ring, a photocationic initiator, and an epoxy compound having a specific structure showed excellent adhesive strength in the cured product and excellent moisture permeation resistance and photocuring as a liquid crystal display sealing material.
[0010]
The present inventors also discovered that using a cationic polymerizable compound and a photocationic initiator and controlling film stiffness strength in light of the correlation between softness and adhesive strength after curing could realize a photocuring resin composition for sealing material having excellent adhesion performance.
[0011]
The present inventors discovered that such a photocuring resin composition for sealing material can be advantageously used in a flat panel such as a liquid crystal display or an electroluminescent display, and so achieved the present invention.
Japanese to English: Pharmaceutical Patent General field: Science Detailed field: Patents
Source text - Japanese http://v3.espacenet.com/publicationDetails/originalDocument?CC=JP&NR=60155111A&KC=A&FT=D&date=19850815&DB=EPODOC&locale=en_EP
Translation - English 3. DETAILED EXPLANATION OF THE INVENTION
The present invention relates to a stable pharmaceutical for external use containing Ketoprofen®, and especially a stable pharmaceutical for external use characterized by distributing an ultraviolet light absorber in a pharmaceutical for external use containing Ketoprofen®.
The present invention also relates to a stable pharmaceutical for external use characterized by also distributing an antioxidant as required. /86
Ketoprofen is an non-steroidal anti-inflammatory drug with excellent anti-inflammatory and analgesic effects. Ketoprofen is a drug widely used to treat, for example, chronic rheumatoid arthritis, osteoarthritis, external wounds, postsurgical analgesic inflammation, and other inflammatory diseases in the surgical field in the form of a pharmaceutical such as oral drug, a suppository, or an injection.
The pharmaceuticals noted above, however, may cause adverse effects such as enteropathy, hepatopathy, or nephropathy, which pose problems for continuous use. Therefore, developing a pharmaceutical for external use, such as an ointment, a gel, a cream, a compress, or a plaster, has been studied, but the stability of the pharmaceutical itself and the stability of the pharmacologically active substance, Ketoprofen, have not been adequately studied, and no satisfactory stable pharmaceutical for external use has yet been achieved.
Specifically, although Ketoprofen is stable over time for a short while when left exposed to sunlight in tablet form, Ketoprofen is extremely unstable over time in a pharmaceutical for external use. Studying the reason for this, the present inventors found that Ketoprofen itself is very unstable against light, and while coating with several layers in tablet form negates the effect of exposure to light, a pharmaceutical for external use is susceptible to the effect of light directly or indirectly.
Ketoprofen is also found to produce two byproducts, 3-ethyl-benzophenone and 3-acetylbenzophenone, when exposed to light.
These two byproducts greatly affect the stability, use feel, and coloration of the pharmaceutical, and are cited as a cause of skin allergies. Therefore, the present inventors carried out extensive studies toward solving these drawbacks in pharmaceuticals for external use containing Ketoprofen, and achieved the stable pharmaceutical for external use of the present invention. That is, the object of the present invention is to provide a stable pharmaceutical for external use containing Ketoprofen.
The present invention was achieved based on the novel finding that distributing an ultraviolet light absorber and, as required, an antioxidant in a pharmaceutical for external use containing Ketoprofen specifically and significantly inhibited photodegradation of Ketoprofen.
The present invention is characterized by distributing an ultraviolet light absorber, for example, a p-aminobenzoic acid derivative, an anthranilic acid derivative, a salicylic acid derivative, a cinnamic acid derivative, a benzophenone derivative, a coumarin derivative, or an amino acid compound, and other ingredients such as ultraviolet light absorbers in a pharmaceutical for external use containing Ketoprofen (including, for example, an ointment, a gel, a cream, a compress, a plaster, a suppository, a liniment, eyedrops, or an aerosol).
More specifically, examples of p-aminobenzoic acid derivatives are p-aminobenzoic acid, esters of p-aminobenzoic acid such as ethyl, propyl, butyl, isobutyl, or monoglycerin ester, p-dimethylaminobenzoic acid and esters thereof such as ethyl or amyl ester, p-diethylaminobenzoic acid and esters thereof such as ethyl or amyl ester, and 2-ethylhexyl p-dimethylaminobenzoate. An anthranilic acid derivative is preferably an ester derivative of anthranilic acid, a specific example of which is anthranilic acid menthyl ester. A salicylic acid derivative is preferably an ester derivative, examples of which are esters of salicylic acid such as menthyl, homomenthyl, ethylene glycol, glycerin, 2-ethylhexyl, tributyl, bornyl, or phenyl, and triethanol ammonium salts of salicylic acid. Examples of cinnamic acid derivatives are cinoxate, diethanolamine p-methoxycinnamate, p-methoxycinnamic acid 2-ethylhexyl ester, and p-acetoamidocinnamic acid isopropyl ester. Examples of benzophenone derivatives are 2,2’-dihydroxy-4,4’-dimethoxybenzophenone, 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-n-octoxybenzophenone, 2,2’-dihydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid, 4-phenylbenzophenone-2-carboxylic acid isooctyl ester, /87
2-hydroxybenzophenone, 2,4-dihydroxybenzophenone, or 2,2’-4,4’-tetrahydroxybenzophenone. Examples of coumarin derivatives are 7-ethylamino-4-methyl coumarin, 7,8-dihydroxycoumarin, 6,7-dihydroxycoumarin, 7-hydroxycoumarin, and 4-methyl-7-hydroxycoumarin. Examples of amino acid compounds are urocanic acid, tryptamine derivatives, and glutamine derivatives. Examples of other ultraviolet light absorbers are benzotriazole derivatives, imidazoline derivatives, pyrimidine derivatives, tetrazole derivatives, dioxane derivatives, furan derivatives, pyrone derivatives, camphor derivatives, nucleic acid derivatives, allantoin derivatives, nicotinic acid derivatives, Lithospermum root, and Vitamin B6 derivatives.
Besides this ultraviolet light absorber, the present invention can also have an antioxidant distributed as required in a pharmaceutical for external use containing Ketoprofen.
Examples of antioxidants are sodium ascorbate, tocopherol (for example, d-, l-, and dl-types such as α-tocopherol, β-tocopherol, γ-tocopherol, or δ-tocopherol) and tocopherol ester derivatives, nordihydroguaiaretic acid, dibutyl hydroxytoluene, butylhydroxyanisole, tert-butyl hydroquinone gallic acid esters (esters such as ethyl, propyl, or isoamyl ester), and 1-oxo-3-methyl-4-isopropylbenzene. Distributing these antioxidants together with an ultraviolet light absorber inhibits photodegradation of Ketoprofen still more, and gives a very stable pharmaceutical for external use.
Next, contents will be discussed. The content of the ultraviolet light absorber is 0.01 to 5 wt%, and preferably 0.1 to 1 wt%, per 100 wt% total weight of the pharmaceutical for external use. The content of the antioxidant is 0.01 to 5 wt%, and preferably 0.05 to 1 wt%, per 100 wt% total weight of the pharmaceutical for external use.
As discussed in detail above, the present invention is characterized by distributing this ultraviolet light absorber and this antioxidant as required in a pharmaceutical for external use containing Ketoprofen as an active ingredient; for example, an ointment, a gel, a cream, a compress, a plaster, a suppository, a liniment, eyedrops, or an aerosol. Distributing these ingredients can achieve the object of the present invention.
More
Less
Experience
Years of experience: 33. Registered at ProZ.com: Jan 2010.
Expertise 
Portfolio 